GLP-1 on Non-ST-Segment Elevation Myocardial Infarction

NCT02577848 · Unknown status

Last updated 2026-05-28

This clinical trial is testing whether a medication called GLP-1 can help improve heart function in adults who have experienced a type of heart attack called non-ST-segment elevation myocardial infarction.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 90 people Planned (estimated).

Who can join Ages 18–80 · all sexes

Timeline Started 2015-10 · est. completion 2016-10

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT02577848 ↗

Description as written by the study sponsor.

The investigators planned to evaluate the effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction (NSTEMI).

Treatments tested

GLP-1 also known as Liraglutide Drug

GLP-1 were taken daily for 7 days
Placebo Drug

Placebo were taken daily for 7 days

Main thing measured	left ventricular ejection fractions
Sponsor	Chinese PLA General Hospital
Conditions studied	Myocardial Infarction
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02577848 ↗